Plasmodium Recombination of Machinery
机械的疟原虫重组
基本信息
- 批准号:7834524
- 负责人:
- 金额:$ 40.49万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-06-05 至 2011-05-31
- 项目状态:已结题
- 来源:
- 关键词:ATP phosphohydrolaseAntigenic DiversityAntigenic VariationBacterial ProteinsBiochemicalCessation of lifeChemicalsChromosomal RearrangementChromosomesCo-ImmunoprecipitationsComplementary DNACulicidaeDNADNA DamageDNA RepairDNA Sequence RearrangementErythrocytesEukaryotaFoundationsFutureGene RearrangementGenesGeneticGenetic RecombinationGenomeGoalsGrowthGrowth and Development functionHomologous GeneImmuneIn VitroInfectionLeadLibrariesLife Cycle StagesLinkMalariaMediatingMediator of activation proteinMeiosisMessenger RNAMesylatesMitosisMolecularMolecular GeneticsOrganismParasitesPhage DisplayPlasmodiumPlasmodium falciparumPlayPropertyProteinsProteomicsReactionRecombinantsResearchRoleScreening procedureStagingSurfaceTestingTranscriptVaccinesWorkbasecrosslinkgene cloninghomologous recombinationimprovedinsightknockout generecombinaserecombinational repairreplication factor Aresponsetherapy developmenttransmission processvaccine development
项目摘要
Malaria parasites, worldwide are responsible for 300-500 million new infections and 1-2 million deaths each year. An effective vaccine, however, remains elusive, partly due to antigenic diversity and the immune evasion strategies of the parasite. Recombination mechanisms are intimately linked with antigenic variation, a phenomenon of utmost significance for vaccine development against protozoan parasites like the malaria parasite. The long term objective of the proposed studies is to investigate mechanism(s) of genetic rearrangements associated with phenomenon like antigenic variation. An underlying tenet of the work proposed is that understanding the recombination mechanisms in Plasmodium will provide improved opportunities for the development of therapies. In other eukaryotes, homologous recombination (HR) plays a major role in chromosomal rearrangements, and Rad51 and Dmc1 proteins, the eukaryotic counterparts of bacterial RecA recombinase, are central molecules involved in HR during mitosis and meiosis. In eukaryotes, additional proteins like RPA and Rad54 functionally cooperate with Rad51 and mediate HR and the repair of damaged chromosomes. The hypothesis underlying proposed studies is that the Rad51 and other interacting proteins, as mediators of HR, play critical role(s) during growth and development of the parasite and facilitate gene rearrangements in P. falciparum. Molecular identification of Rad51 and Dmc1 homologues in P. falciparum and recent characterization of enzymatic properties of recombinant PfRad51, such as DNA strand exchange and ATPase activities, have strongly indicated a conserved functional role for PfRad51 in these organisms. We will test our hypothesis using biochemical as well as genetic approaches. Studies in the revised specific aims 1 and 2 will lead to in vitro characterization of the proteins involved in HR and thus probe into the biochemical basis of recombination and gene rearrangements in the parasites. PfRad51 gene knockout studies in the revised specific aim 3 will directly evaluate importance of PfRad51 in the erythrocytic growth of the parasite and analysis of repertoire of var gene transcripts. Moreover, studies on Dmc1 disruption (revised specific aim 3) will evaluate the role of meiosis specific recombinase during malaria transmission. The results of this study should be important in unraveling the recombination machinery and molecular and genetic basis for recombination and genetic rearrangements in P. falciparum.
全世界的疟疾寄生虫每年造成300-5亿新感染和1-200万人死亡。然而,一种有效的疫苗仍然难以捉摸,部分原因是抗原多样性和寄生虫的免疫逃避策略。重组机制与抗原差异密切相关,这是疫苗发育对原生动物寄生虫(如疟原虫)的最大意义的现象。拟议研究的长期目标是研究与现象(如抗原变异)相关的遗传重排机制。提出的工作的基本宗旨是了解疟原虫中的重组机制将为疗法开发提供改善的机会。在其他真核生物中,同源重组(HR)在染色体重排中起主要作用,而细菌RECA重组酶的真核生物对应物RAD51和DMC1蛋白是在有点和质膜病期间与HR相关的中枢分子。在真核生物中,其他蛋白质(如RPA和RAD54)在功能上与RAD51合作,并介导HR以及修复受损的染色体。拟议的研究的基本假设是,作为人力资源介质的Rad51和其他相互作用的蛋白质在寄生虫的生长和发展过程中起着至关重要的作用,并促进了恶性疟原虫的基因重排。恶性疟原虫中RAD51和DMC1同源物的分子鉴定以及重组PFRAD51的酶促性能的最新表征,例如DNA链交换和ATPase活性,强烈表明PFRAD51在这些生物体中具有保守的功能作用。我们将使用生化和遗传方法检验假设。在修订的特定目的1和2中的研究将导致涉及HR的蛋白质的体外表征,从而探测寄生虫重组和基因重排的生化基础。 PFRAD51在修订的特定目标3中的基因敲除研究将直接评估PFRAD51在寄生虫的红细胞生长中的重要性和VAR基因转录物库的分析。此外,关于DMC1破坏的研究(修订的特定目标3)将评估减数分裂特异性重组酶在疟疾传播过程中的作用。这项研究的结果对于揭开重组机制以及恶性疟原虫重组和遗传重排的分子和遗传基础应该很重要。
项目成果
期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Novel nanosomes for gene delivery to Plasmodium falciparum-infected red blood cells.
- DOI:10.1038/srep01534
- 发表时间:2013
- 期刊:
- 影响因子:4.6
- 作者:Gopalakrishnan, Anusha M.;Kundu, Anup K.;Mandal, Tarun K.;Kumar, Nirbhay
- 通讯作者:Kumar, Nirbhay
Aberrant sporogonic development of Dmc1 (a meiotic recombinase) deficient Plasmodium berghei parasites.
- DOI:10.1371/journal.pone.0052480
- 发表时间:2012
- 期刊:
- 影响因子:3.7
- 作者:Mlambo G;Coppens I;Kumar N
- 通讯作者:Kumar N
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Nirbhay Kumar其他文献
Nirbhay Kumar的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Nirbhay Kumar', 18)}}的其他基金
Combination Vaccines to Interrupt Malaria Transmission
阻断疟疾传播的联合疫苗
- 批准号:
9750618 - 财政年份:2017
- 资助金额:
$ 40.49万 - 项目类别:
Combination Vaccines to Interrupt Malaria Transmission
阻断疟疾传播的联合疫苗
- 批准号:
9381629 - 财政年份:2017
- 资助金额:
$ 40.49万 - 项目类别:
Identification of Transmission blocking epitopes on P. vivax 48/45 protein
间日疟原虫 48/45 蛋白上传播阻断表位的鉴定
- 批准号:
8986156 - 财政年份:2014
- 资助金额:
$ 40.49万 - 项目类别:
Rational Approach to Optimize Immune Potency of DNA Vaccines
优化 DNA 疫苗免疫效力的合理方法
- 批准号:
8676649 - 财政年份:2013
- 资助金额:
$ 40.49万 - 项目类别:
Rational Approach to Optimize Immune Potency of DNA Vaccines
优化 DNA 疫苗免疫效力的合理方法
- 批准号:
8535062 - 财政年份:2013
- 资助金额:
$ 40.49万 - 项目类别:
Malaria Vaccine Adjuvant Immunogenicity and Safety
疟疾疫苗佐剂的免疫原性和安全性
- 批准号:
8351069 - 财政年份:2012
- 资助金额:
$ 40.49万 - 项目类别:
Malaria Vaccine Adjuvant Immunogenicity and Safety
疟疾疫苗佐剂的免疫原性和安全性
- 批准号:
8515930 - 财政年份:2012
- 资助金额:
$ 40.49万 - 项目类别:
A DNA vaccine to prevent transmission of human malaria
预防人类疟疾传播的 DNA 疫苗
- 批准号:
7893555 - 财政年份:2010
- 资助金额:
$ 40.49万 - 项目类别:
MALARIA RESEARCH AND TRAINING PROGRAM IN ZIMBABWE
津巴布韦疟疾研究和培训项目
- 批准号:
6395018 - 财政年份:2000
- 资助金额:
$ 40.49万 - 项目类别:
相似国自然基金
靶向前列腺特异性膜抗原PSMA的小分子影像试剂的研究
- 批准号:21877004
- 批准年份:2018
- 资助金额:63.0 万元
- 项目类别:面上项目
自身反应性CD4+ T细胞在缺血性脑损伤中的作用机制研究
- 批准号:81771274
- 批准年份:2017
- 资助金额:54.0 万元
- 项目类别:面上项目
利用质谱为基础的蛋白基因组学方法发现和分析肿瘤特异性新抗原
- 批准号:31670949
- 批准年份:2016
- 资助金额:60.0 万元
- 项目类别:面上项目
普罗威登斯菌O抗原多样性进化机制及其与细菌致病性关系的系统研究
- 批准号:81471904
- 批准年份:2014
- 资助金额:72.0 万元
- 项目类别:面上项目
文昌鱼免疫相关细胞的鉴定及抗原受体多样性产生机制的起源研究
- 批准号:31470846
- 批准年份:2014
- 资助金额:85.0 万元
- 项目类别:面上项目
相似海外基金
Point-of-care diagnostic test for T. cruzi (Chagas) infection
克氏锥虫(恰加斯)感染的即时诊断测试
- 批准号:
10603665 - 财政年份:2023
- 资助金额:
$ 40.49万 - 项目类别:
Targeting glycoprotein (G) domain-III for pan-lyssavirus nanobody therapeutics
靶向糖蛋白 (G) 结构域 III 用于泛狂犬病病毒纳米抗体治疗
- 批准号:
10667756 - 财政年份:2023
- 资助金额:
$ 40.49万 - 项目类别:
Identification of serological markers of protection and risk for dengue vaccines and natural infection
鉴定登革热疫苗和自然感染的保护和风险的血清学标记
- 批准号:
10638037 - 财政年份:2023
- 资助金额:
$ 40.49万 - 项目类别:
Evaluating the Functional Impact of Genetic Diversity on Malaria Vaccine Candidates
评估遗传多样性对候选疟疾疫苗的功能影响
- 批准号:
10707438 - 财政年份:2022
- 资助金额:
$ 40.49万 - 项目类别:
Predictive fitness models for influenza vaccine strain selection
流感疫苗株选择的预测适应性模型
- 批准号:
10350139 - 财政年份:2022
- 资助金额:
$ 40.49万 - 项目类别: